Literature DB >> 29626738

Return on Investment Analysis of Breast Cancer Screening and Downstaging in Egypt: Implications for Developing Countries.

Alena N Skrundevskiy1, Omar S Omar2, Jungyoon Kim3, Amr S Soliman4, Theodore A Korolchuk5, Fernando A Wilson1.   

Abstract

OBJECTIVE: The aim of this study was to perform a return-on-investment (ROI) analysis of a breast cancer screening program in Egypt by comparing net profit in treatment costs saved to program cost investment.
METHODS: The breast cancer downstaging program targeted women living in an Egyptian slum, where residents have low access to health care. Program costs were estimated by using data from interviews with program administrative staff. Screening and treatment costs were estimated by using Ministry of Health medical reimbursement data. Estimates for expected rates of downstaging were modeled on the basis of data from a previous study. ROI, or relative cost savings, was calculated by comparing treatment cost savings to costs for the screening program. A baseline ROI for facility-based screening was calculated, followed by ROIs for different scenarios.
RESULTS: Average per-person treatment cost for screened and unscreened patients was estimated to be $28,632 and $58,170, respectively, with a cumulative lifetime risk of 6.36%. Total screening program cost per person was $112.10. The study estimated an expected decrease in late-stage breast cancer diagnosis by 13.7% as a result of the screening program, saving $4,049 in treatment costs per individual diagnosed. The analysis resulted in a positive ROI of 133% for facility-based screening.
CONCLUSIONS: Breast cancer represents an increasing burden on health care in Egypt and other developing countries. This study concludes that a community-based downstaging program resulted in a positive ROI, or overall cost-savings. The findings inform that policymakers in low-income and middle-income countries may consider implementing community-based downstaging programs for breast cancer.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Egypt; breast cancer; cancer screening; community; developing countries; downstaging; return-on-investment

Mesh:

Year:  2018        PMID: 29626738     DOI: 10.1016/j.vhri.2018.01.006

Source DB:  PubMed          Journal:  Value Health Reg Issues        ISSN: 2212-1099


  6 in total

1.  Return on Investment of a Breast Cancer Screening Program in Tanzania: Opportunity for Patient and Public Education.

Authors:  Zoe Heisler; Betsy Eastwood; Julius Mwaiselage; Crispin Kahesa; Khadija Msami; Amr S Soliman
Journal:  J Cancer Educ       Date:  2020-09-27       Impact factor: 1.771

2.  Does National Colorectal Cancer Screening Program Represent Good Value for Money? Results from a Return-on-Investment Model in Vietnam.

Authors:  Nguyen Quynh Anh; Nguyen Thu Ha
Journal:  Health Serv Insights       Date:  2021-05-24

3.  Breast Cancer Screening in Low-Income Countries: A New Program for Downstaging Breast Cancer in Tanzania.

Authors:  Darcy S Cherlin; Julius Mwaiselage; Khadija Msami; Zoe Heisler; Heather Young; Qingwei Cui; Amr S Soliman
Journal:  Biomed Res Int       Date:  2022-04-05       Impact factor: 3.411

4.  Return on Investment of Free Colorectal Cancer Screening Tests in a Primarily Rural Uninsured or Underinsured Population in Northeast Texas.

Authors:  Gabriela Orsak; Anastasia Miller; Carlton M Allen; Karan P Singh; Paul McGaha
Journal:  Pharmacoecon Open       Date:  2020-03

5.  Factors associated with Late-Stage Diagnosis of Breast Cancer among Egyptian Women.

Authors:  Horeya M Ismail; Samiha Mokhtar; Hazem El-Mansy
Journal:  J Public Health Res       Date:  2022-05-16

6.  Designing an Effective Colorectal Cancer Screening Program in Egypt: A Qualitative Study of Perceptions of Egyptian Primary Care Physicians and Specialists.

Authors:  Lori Brand Bateman; Somaia Khamess; Salah-Eldin Abdelmoneim; Waleed Arafat; Mona N Fouad; Yomna Khamis; Abbas Omar; Randa Salah Abdelmoneim; Isabel Scarinci
Journal:  Oncologist       Date:  2020-02-24       Impact factor: 5.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.